Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Baciarello · SciRah

Researcher profile · Semantic Scholar

G. Baciarello

Share profile

G. Baciarello — researcher profile on SciRah

h-index: 21
Works: 85
Citations: 1,874

Most-cited papers

A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
K. Fizazi, A. Maillard, N. Penel, G. Baciarello +16 more
2019Annals of Oncology205 citations Open access
Semantic Scholar
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
A. Krämer, T. Bochtler, C. Pauli, G. Baciarello +11 more
2022Annals of Oncology191 citations Open access
Semantic Scholar
Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers
F. Danlos, Claudia Grajeda-Iglesias, S. Durand, A. Sauvat +36 more
2021Cell Death and Disease150 citations Open access
Semantic Scholar
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
J. Graff, G. Baciarello, A. J. Armstrong, C. Higano +8 more
2016Annals of Oncology117 citations
Semantic Scholar
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
L. Albiges, S. Foulon, A. Bayle, B. Gachot +27 more
2020Nature Cancer113 citations Open access
Semantic Scholar
New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
E. Rassy, P. Parent, F. Lefort, S. Boussios +2 more
2020Critical reviews in oncology/hematology102 citations Open access
Semantic Scholar
Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.
F. Ruatta, L. Derosa, B. Escudier, Emeline Colomba +5 more
2019European Journal of Cancer88 citations
Semantic Scholar
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design
J. Ross, E. Sokol, H. Moch, L. Mileshkin +8 more
2020The Oncologist67 citations Open access
Semantic Scholar
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience
C. Pauli, T. Bochtler, L. Mileshkin, G. Baciarello +12 more
2021The Oncologist62 citations Open access
Semantic Scholar
Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
Luc Cabel, Elika Loir, G. Gravis, P. Lavaud +5 more
2017Journal of Immunotherapy for Cancer56 citations Open access
Semantic Scholar
Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors.
A. Fuerea, G. Baciarello, A. Patrikidou, L. Albiges +5 more
2016European Journal of Cancer50 citations
Semantic Scholar
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
T. Olivier, E. Fernández, I. Labidi-Galy, P. Dietrich +4 more
2021Cancer Treatment Reviews48 citations Open access
Semantic Scholar
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.
M. Gizzi, L. Obéric, C. Massard, A. Poterie +9 more
2016European Journal of Cancer44 citations
Semantic Scholar
Fatigue and physical activity in cancer survivors: A cross‐sectional population‐based study
M. Matias, G. Baciarello, Mohamed Neji, A. di Meglio +7 more
2019Cancer Medicine43 citations Open access
Semantic Scholar
Randomized controlled trial of remote endarterectomy versus endovascular intervention for TransAtlantic Inter-Society Consensus II D femoropopliteal lesions.
R. Gabrielli, M. S. Rosati, S. Vitale, G. Baciarello +4 more
2012Journal of Vascular Surgery40 citations Open access
Semantic Scholar
Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
L. Derosa, B. Routy, D. Enot, G. Baciarello +6 more
201733 citations
Semantic Scholar
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study.
G. Baciarello, M. Özgüroğlu, S. Mundle, G. Leitz +6 more
2021European Journal of Cancer30 citations Open access
Semantic Scholar
Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
N. Delanoy, A. Hardy-Bessard, E. Efstathiou, S. Le Moulec +34 more
2018European Urology Oncology30 citations
Semantic Scholar
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
G. Baciarello, R. Delva, G. Gravis, Y. Tazi +17 more
2021European Urology27 citations Open access
Semantic Scholar
Advancing therapies in metastatic castration-resistant prostate cancer
G. Baciarello, M. Gizzi, K. Fizazi
2018Expert Opinion on Pharmacotherapy26 citations
Semantic Scholar
Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma
S. Astore, G. Baciarello, L. Cerbone, F. Calabrò
2023Cancer Drug Resistance24 citations Open access
Semantic Scholar
A qualitative evaluation of the use of interventions to treat fatigue among cancer survivors: A healthcare provider's view.
E. Martin, A. Zingarello, A. di Meglio, G. Baciarello +6 more
2020European Journal of Cancer Care22 citations Open access
Semantic Scholar
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer
R. Flippot, A. Patrikidou, M. Aldea, E. Colomba +13 more
2022Drugs21 citations
Semantic Scholar
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
P. Lavaud, C. Dumont, C. Thibault, L. Albiges +6 more
2020Therapeutic Advances in Medical Oncology21 citations Open access
Semantic Scholar
Management of germ cell tumors during the outbreak of the novel coronavirus disease-19 pandemic: a survey of international expertise centers.
L. Nappi, M. Ottaviano, P. Rescigno, M. Tortora +30 more
2020The Oncologist20 citations Open access
Semantic Scholar
Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II).
M. S. Rosati, C. Raimondi, G. Baciarello, Paolo Grassi +6 more
2011Annals of Oncology20 citations Open access
Semantic Scholar
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma
P. Parent, É. Auclin, A. Patrikidou, L. Mezquita +14 more
2023Cancers18 citations Open access
Semantic Scholar
Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome.
E. Colomba, Grégoire Marret, G. Baciarello, P. Lavaud +8 more
2020European Journal of Cancer18 citations
Semantic Scholar
Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group
M. Guérin, C. Miran, E. Colomba, M. Cabart +21 more
2023Frontiers in Oncology17 citations Open access
Semantic Scholar
Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy.
A. Krämer, F. Losa, L. Gay, D. Page +7 more
2018Annals of Oncology16 citations Open access
Semantic Scholar
Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
C. Thibault, J. Eymard, A. Birtle, M. Krainer +14 more
2018European Journal of Cancer12 citations
Semantic Scholar
Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions.
A. Krämer, F. Losa, E. Sokol, D. Page +7 more
201812 citations
Semantic Scholar
Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide.
G. Baciarello, C. Sternberg
2016Critical reviews in oncology/hematology12 citations
Semantic Scholar
876PEfficacy of cabozantinib (C) after PD-1/PD-L1 checkpoint inhibitors in metastatic renal cell carcinoma (mRCC): The Gustave Roussy experience
L. Derosa, J. Rouche, Emeline Colomba, G. Baciarello +3 more
201711 citations Open access
Semantic Scholar
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
M. Aldea, L. Lam, E. Orillard, Casilda Llácer Pérez +20 more
2021European Journal of Cancer10 citations Open access
Semantic Scholar
Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?
A. Patrikidou, T. Zilli, G. Baciarello, Safae Terisse +2 more
2021Therapeutic Advances in Medical Oncology9 citations Open access
Semantic Scholar
Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial.
C. Dumont, G. Baciarello, P. Bosset, P. Lavaud +8 more
2020Clinical Genitourinary Cancer8 citations Open access
Semantic Scholar
QualFatigue study: which factors influence the use of specific interventions for breast cancer survivors with fatigue? A cross-sectional exploratory study
C. Charles, A. di Meglio, M. Arnedos, Johanna Arvis +11 more
2021Supportive Care in Cancer7 citations Open access
Semantic Scholar
Etoricoxib and anastrozole in adjuvant early breast cancer: ETAN trial (phase III).
M. S. Rosati, M. di Seri, G. Baciarello, V. L. Russo +5 more
2011Journal of Clinical Oncology7 citations
Semantic Scholar
Clinical outcomes and safety in men ≥ 75 and < 75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trial.
J. Graff, G. Baciarello, A. Armstrong, C. Higano +7 more
20156 citations
Semantic Scholar
Previous enzalutamide therapy and response to subsequent taxane therapy in metastatic castration-resistant prostate cancer.
M. Gizzi, G. Baciarello, A. Flechon, P. Beuzeboc +15 more
20156 citations
Semantic Scholar
Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy.
A. Terbuch, F. Posch, T. Bauernhofer, P. Jost +23 more
2022International Journal of Radiation Oncology, Biology, Physics5 citations Open access
Semantic Scholar
Association of the Lung Immune Prognostic Index with outcome in patients with metastatic urothelial cancer treated with immune checkpoint inhibitor.
P. Pauline, É. Auclin, L. Mezquita, N. M. Chanzá +11 more
2020Journal of Clinical Oncology5 citations
Semantic Scholar
Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial.
P. Giannatempo, V. Guadalupi, L. Marandino, D. Raggi +16 more
2023Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Biomarker-driven immunotherapy for precision medicine in prostate cancer.
A. Ottini, P. Sepe, T. Beninato, M. Claps +6 more
2021Personalized Medicine4 citations
Semantic Scholar
A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience
C. Pauli, T. Bochtler, L. Mileshkin, G. Baciarello +12 more
2019Annals of Oncology4 citations Open access
Semantic Scholar
Comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients (pts) for targeted or immunotherapy treatment (tx) using the prospective CUPISCO trial’s criteria
J. Ross, E. Sokol, H. Moch, L. Mileshkin +13 more
2019Annals of Oncology4 citations Open access
Semantic Scholar
Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC).
C. Thibault, J. Eymard, A. Hardy-Bessard, A. Birtle +14 more
20174 citations
Semantic Scholar
Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
F. Recine, G. Ceresoli, G. Baciarello, L. Cerbone +1 more
2015The Quarterly Journal of Nuclear Medicine and Molecular Imaging4 citations
Semantic Scholar
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors
Sara Mokbel, G. Baciarello, P. Lavaud, Aurelius Omlin +18 more
2024Cancers3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Fizazi×18
Invite
K. Fizazi — researcher profile on SciRah
Y. Loriot×13
Invite
Y. Loriot — researcher profile on SciRah
L. Albiges×12
Invite
L. Albiges — researcher profile on SciRah
E. Colomba×9
Invite
E. Colomba — researcher profile on SciRah

×8

Invite

A. Patrikidou — researcher profile on SciRah

Invite

P. Lavaud — researcher profile on SciRah

Invite

A. Flechon — researcher profile on SciRah

Invite

A. Krämer — researcher profile on SciRah

Invite

H. Moch — researcher profile on SciRah

Invite

B. Escudier — researcher profile on SciRah

Invite

C. Massard — researcher profile on SciRah

L. Mileshkin×5

Invite

L. Mileshkin — researcher profile on SciRah